88
Participants
Start Date
May 31, 2015
Primary Completion Date
August 31, 2018
Study Completion Date
August 31, 2018
MM-141
Placebo
Gemcitabine
Nab-Paclitaxel
Columbia University Medical Center, New York
Columbia University, New York
North Shore Hematology Oncology Associates, PC, East Setauket
Vivantes Klinikum Neukoelln, Berlin
Roswell Park Cancer Inst, Buffalo
St. Luke's University Health Network, Bethlehem
Fox Chase Cancer Center, Philadelphia
Hospital General Universitario Gregorio Marañon, Madrid
Centro Integral Oncologico Clara Campal, Madrid
Cancer Treatment Centers of America-Georgia, Newnan
Memorial Regional Hospital, Pembroke Pines
Vanderbilt-Ingram Cancer Ctr, Nashville
Hospital Universitario Marques de Valdecilla, Santander
Hospital Clinico Universitario de Valencia, Valencia
Universitaetsklinikum Koeln, Cologne
Oncology Specialists, S.C., Park Ridge
Northwestern University, Chicago
University of Illinois at Chicago, Chicago
Caritasklinik St. Theresia, Saarbrücken
Cancer Center of Acadiana Research Department, Lafayette
Brooke Army Medical Center (BAMC), Fort Sam Houston
Klinikum rechts der Isar - TUM, München
Banner MD Anderson Cancer Ctr., Gilbert
UCLA School of Medicine, Los Angeles
Cancer Care Assoc Med Grp, Redondo Beach
Pacific Cancer Medical Center, Inc., Anaheim
St. Jude Heritage Healthcare, Fullerton
Sansum Clinic, Santa Barbara
Central Coast Med Onc Corp, Santa Maria
UCSF Cancer Center, San Francisco
Cancer Care Northwest, P.S., Spokane Valley
Rocky Mountain Cancer Centers, Aurora
Baptist Health Med Gr Onc, LLC, Miami
Florida Cancer AffiliatesOcala, Ocala
Illinois Cancer Specialists, Chicago
Midwest Regional Medical Cntr, Zion
Nylen Cancer Center, Sioux City
Compr Cancer Centers of Nevada, Henderson
New York Oncology HematologyPC, Albany
Bassett Cancer Institute, Cooperstown
Mid Ohio Onco/ Zangmeister Ctr, Columbus
Tulsa Cancer Institute, PLLC, Tulsa
Allegheny Cancer Center, Pittsburgh
SCRI - Tennessee Oncology, Nashville
Texas Oncology-Austin Midtown, Austin
Texas Oncology P A Bedford, Bedford
Texas Oncology-Dallas P.H., Dallas
Texas Oncology-Paris, Paris
Texas Oncology-Plano East, Plano
Texas Oncology SA Medical Ctr, San Antonio
Texas Oncology-Tyler, Tyler
Virginia Cancer Specialists PC, Fairfax
Onc and Hem Asso of SW VA Inc, Salem
Northwest Cancer SpecialistsPC, Vancouver
Charite Universitaetsmd Berlin, Berlin
Uniwersyteckie Centrum Kliniczne, Gdansk
WSZ im. L. Rydygiera wToruniu, Torun
Hospital U de Fuenlabrada, Madrid
Royal Marsden Hospital, Sutton
Reliant Medical Group, Inc., Worcester
Cross Cancer Institute, Edmonton
Hospital Universitari Vall d'Hebron, Barcelona
Guy's Hospital, London
Sarah Cannon Research Institute UK, London
The Christie, Manchester
Royal Marsden Hospital, Sutton
Lead Sponsor
Merrimack Pharmaceuticals
INDUSTRY